Since March 2018, Pinder Sahota has been General Manager and Corporate Vice President of Novo Nordisk UK. In his role, Pinder is passionate about improving the lives of people living with diabetes, obesity, rare blood, and endocrine disorders – whether that is by driving research and innovation into key therapeutic areas, challenging health inequalities that exist in our communities or partnering with the NHS to deliver better health outcomes.
Pinder started his pharmaceutical career as a graduate, in a sales and marketing role with the companies which formed Sanofi Aventis. He has since held a variety of senior commercial and leadership roles across Europe for companies including GSK, AstraZeneca, and Smith & Nephew. A champion of collaboration and dedication within the industry, Pinder has been an active member of the ABPI board for 3 years. As well as his newly appointed role of Vice President of the Association of the British Pharmaceutical Industry, Pinder is also Vice Chair of the European Medicines Group.